EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY

Month: April 2024

Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair

April 24, 2024

Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK: Harness Therapeutics, a biotechnology company focused on protein upregulation to develop

Read »

Kynos Therapeutics Announces Positive Top Line Results From the First-In-Human Phase I Study of its KMO Inhibitor, KNS366, Demonstrating Safety, Tolerability and Target Engagement

April 23, 2024

Edinburgh, UK – Kynos Therapeutics Ltd, a clinical stage biotechnology company developing first-in-class small molecule kynurenine 3-monooxygenase (KMO) inhibitors for acute and chronic inflammatory disorders,

Read »

Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor

April 17, 2024

Oxford, UK: Theolytics, a biotechnology company developing next-generation oncolytic viral therapies, today announced it has successfully closed its latest financing round, raising a total of

Read »

EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY

Month: April 2024

Harness Therapeutics Appoints Seasoned Biopharmaceutical Leader, Ms. Meenu Chhabra Karson, as Board Chair

Kynos Therapeutics Announces Positive Top Line Results From the First-In-Human Phase I Study of its KMO Inhibitor, KNS366, Demonstrating Safety, Tolerability and Target Engagement

Theolytics successfully closes latest financing raising total of £19M ($24.5M) and welcomes Sound Bioventures as new investor

Categories

Archives